Podcasts about Uptake

Thabo Shole-Mashao, speaks to Benji Seitlhamo who is the Acting Director of Economic Development Facilitation at the City of Johannesburg to discuss concerns over the slow uptake spaza shop support fund. The R500 million fund was launched in April this year. The Clement Manyathela Show is broadcast on 702, a Johannesburg based talk radio station, weekdays from 09:00 to 12:00 (SA Time). Clement Manyathela starts his show each weekday on 702 at 9 am taking your calls and voice notes on his Open Line. In the second hour of his show, he unpacks, explains, and makes sense of the news of the day. Clement has several features in his third hour from 11 am that provide you with information to help and guide you through your daily life. As your morning friend, he tackles the serious as well as the light-hearted, on your behalf. Thank you for listening to a podcast from The Clement Manyathela Show. Listen live on Primedia+ weekdays from 09:00 and 12:00 (SA Time) to The Clement Manyathela Show broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/XijPLtJ or find all the catch-up podcasts here https://buff.ly/p0gWuPE Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

Jeff Goad, PharmD, MPH, joined Over the Counter to discuss hepatitis A and B vaccines and the ways in which pharmacists can play their role in boosting vaccine uptake and reducing hesitancy.

What is it about Korn Ferry's video-podcast series, the Briefings Podcast, that has attracted more than 16,000 email subscribers just one year after launch and as many as 120,000 views per episode? In this episode, Bob Buday speaks with returning guest Jonathan Dahl, Korn Ferry vice president and chief content officer, about the strategy behind the Briefings Podcast, the key lessons he has learned about podcasting, and the surprisingly low cost of producing a podcast.

Un nouvel épisode du Pharmascope est maintenant disponible! Dans de ce 136ème épisode, Nicolas, Isabelle et un invité discutent de la prophylaxie pré-exposition au VIH dans diverses situations à risque.  Les objectifs pour cet épisode sont : Résumer et comparer les modalités de prise en charge de la PrEP Identifier les patients pouvant bénéficier de la PrEP Discuter des avantages et des risques associés à la prise de la PrEP   Ressources pertinentes en lien avec l'épisode Baril JG et coll. La prophylaxie préexposition au virus de l'immunodéficience humaine : Guide pour les professionnels de la santé du Québec. Ministère de la santé et des services sociaux. Janvier 2019. Disponible, en ligne. US Public Health Services.Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update. A Clinical Practice Guideline. 2021. Disponible, en ligne. Grant RM et coll; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. Grant RM et coll; iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820-9. McCormack S et coll. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53-60. Molina JM et coll; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237-46. Baeten JM et coll; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410. Choopanya K et coll; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-90.

Today on What's Right:The Biden-Hur interview was even worse than we thoughtJoe Biden hid prostate cancerWho is implicated in the Joe Biden cover upTake caution pursuing Biden cover up legally!Shooting at Las Vegas Athletic ClubKash Patel and Dan Bongino on current FBI investigationsTrump has two hour call with Vladimir PutinThanks for tuning into today's episode of What's Right! If you enjoyed this episode, subscribe to the show on Spotify or Apple Podcasts, and make sure you leave us a 5-star review.Have personal injury questions? Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sam & Ash Injury Law⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to get free answers 24/7.Connect with us on our socials:TWITTERSam ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@WhatsRightSam⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠What's Right Show ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@WhatsRightShow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠FACEBOOKWhat's Right Show ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/WhatsRightShow/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠INSTAGRAMWhat's Right Show ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@WhatsRightShow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠EMAILSam sam@whatsrightshow.comProducer Robbie robbie@whatsrightshow.comTo request a transcript of this episode, email ⁠⁠marketing@samandashlaw.com

Today's guest, our 200th guest on the Hoffman Podcast, is Brad Keywell. As you'll soon hear, Brad is expansively curious and always moving toward more aliveness. An entrepreneur, investor, professor, author, artist, philanthropist, and Hoffman graduate, he shares his personal experience of the Process with us. In addition, Brad reflects upon the Hoffman Process through his lens of entrepreneurship and his essentially curious nature. Brad sees life as two forks in the road:  one of curiosity (fully alive) and the other of stagnation (not yet dead). While he says these are extremes, Brad suggests it is important to know which fork we find ourselves on and then consciously consider if we're happy where we are. For Brad, this choice is to live the path of being fully alive. He suggests that the Process is a tool to help us grow in greater aliveness, curiosity, and vulnerability. We can consciously choose to continue to move forward into a life of greater aliveness and expansive curiosity. Join us in celebrating Brad and his journey to and through the Hoffman Process. We are grateful for this conversation with Brad and Drew. We hope you enjoy exploring the nature of change, curiosity, and a life of more aliveness. More about Brad Keywell: Brad is an American entrepreneur, investor, professor, author, artist, and philanthropist. He has founded or co-founded nine technology companies (three of which have gone public on NASDAQ), an early-stage VC firm, a global ideas platform, an immersive museum, and several nonprofit organizations. Brad was named the overall 2019 EY World Entrepreneur of the Year. This is the highest global honor (selected from 44 country winners in the global EY Entrepreneur of the Year program). He was also awarded the 2018 overall EY Entrepreneur of the Year in the United States. He is the Founder and Executive Chairman of Uptake Technologies. Uptake is an Industrial AI software company that delivers insights that increase productivity and reliability for industrial operators in twenty-one countries. In addition, Uptake, a Technology Pioneer of the World Economic Forum, was Forbes Startup of the Year in 2015. In addition, Uptake is a three-time CNBC Disruptor, a three-time Forbes Cloud 100 member, and was ranked third on the Forbes AI 50 list. Brad signed The Giving Pledge in 2015. By doing so, he committed to giving the majority of his wealth to charitable causes. He is the chairman of Future Founders, a nonprofit that provides entrepreneurship education to students in underserved communities throughout Chicagoland. Follow Brad on LinkedIn and X(Twitter). As mentioned in this episode: Bob Hoffman: Bob Hoffman, founder of the Hoffman Process, had an innate and highly gifted ability to listen to deeper truths and wisdom. Read more... University of Michigan Ross Commencement 2022 Speaker: Brad Keywell •   Bo Schembechler, Football Coach, University of Michigan

Dr. Kenneth Ruggiero (Medical University of South Carolina, Charleston) joins AJP Audio to discuss the the effectiveness of an app-based intervention at reducing the symptoms of sleeplessness and posttraumatic stress in a broad cohort in the wake of a natural disaster.  Afterwards, AJP Editor-in-Chief Dr. Ned Kalin puts the rest of the May issue into context. 00:38     Ruggiero interview 03:13     Bounce Back Now app 05:03     Natural disasters and other sources of trauma 07:31     Low cost and broad-based intervention 08:49     Limitations 10:19     Changes in how the intervention was designed 11:17     Uptake and interactions with the app 13:15     Future directions 14:36     Kalin interview 14:50     Ruggiero et al. 19:26     Norman et al. 23:29     Conrod et al. 27:53     Olfson et al. 31:44     Olfson et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

Only half of fathers take paternity leave. That's according to a new report from The Irish Human Rights and Equality Commission and the Economic and Social Research Institute. Speaking to Shane this morning was Dr Claire Keane, Associate Research Professor with ESRI & Co-Author of the report.

Only half of fathers take paternity leave. That's according to a new report from The Irish Human Rights and Equality Commission and the Economic and Social Research Institute. Speaking to Shane this morning was Dr Claire Keane, Associate Research Professor with ESRI & Co-Author of the report.

Professor Barbara Ryan, Consultant Gastroenterologist and Clinical Professor, Trinity College Dublin says that life saving bowel cancer screening uptake is going backwards.

While there are 70 extra apprenticeships offered in Ireland there is still a gap in their uptake. Why is this? Ivan discussed this further with Paddy Kavanagh, General Secretary of Connect Trade Union and also Guidance Counsellor Brian Mooney

On this week's MyAgLife in Fertilization episode, NEWAGE Laboratories' Jenny Garley explains how leaf brix measurements can be used to assess nutrient uptake in crops, particularly macronutrient uptake.   Supporting the People who Support Agriculture Thank you to this month's sponsors who makes it possible to get you your daily news. Please feel free to visit their website. Dormex (Alzchem Group) - https://www.alzchem.com/en/brands/dormex/ Deerpoint Group, Inc. - https://deerpointgroup.com/dpg-potassium-plus/ KIM-1C, LLC - https://www.linkedin.com/company/kim-c1-llc/

Pediatrician Christina Suh discusses the KevinMD article, "More than just the flu: Helping families and doctors prepare for pan-respiratory viruses." In this episode, Christina addresses the challenges of the current pan-respiratory season, including RSV, COVID, and the flu, emphasizing the critical role of vaccines in saving lives. She explores the concept of closing the intention gap to support individuals who want to get vaccinated by making the process easier, rather than focusing solely on vaccine hesitancy. Christina highlights the overwhelming burden on health care providers to communicate complex vaccination guidelines and presents digital messaging strategies that effectively increase vaccine uptake without adding to provider workload. Additionally, she discusses the U.S. Department of Health and Human Services' Risk Less. Do More. campaign and offers actionable strategies for health care systems to enhance patient engagement and improve vaccination rates. Our presenting sponsor is DAX Copilot by Microsoft. DAX Copilot, by Microsoft, is your AI assistant for automated clinical documentation and workflows. DAX Copilot allows physicians to do more with less and turn their words into a powerful productivity tool. DAX Copilot automates clinical documentation—making it available in the EHR within minutes—and clinical workflows, including referral letters, after-visit summaries, style and formatting customizations, and more. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Discover AI-powered solutions for clinical documentation and workflows. Click here to see a 12-minute DAX Copilot demo. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus

Ondo InsurTech PLC (LSE:ONDO) CEO Craig Foster talked with Proactive about the company's latest trading update and its expanding presence in the United States. The company has signed a pilot deal with Liberty Mutual Insurance, one of the largest home insurers in the US, marking a significant milestone in its growth strategy. Foster highlighted that Liberty Mutual is the sixth-largest personal lines insurer and a Fortune 100 company. This new partnership follows Ondo's successful collaboration with Nationwide, which expanded its LeakBot rollout from Ohio to 16 states. The company's US operations now account for 65% of new business growth, with a remarkable 400% year-on-year increase. Revenue is forecasted to grow by 70% this year, and achieve profitablity in the second half of the next financial year. Foster emphasised that a shift to a prepayment model has eliminated the need for additional capital raises, strengthening the company's financial position. Beyond the US, Ondo continues to grow in the UK and Scandinavia. A new partnership with NFU in the UK is already showing positive results, further reinforcing the company's expansion strategy. Watch the full interview to learn more about Ondo InsurTech's latest developments. Don't forget to like this video, subscribe to our channel, and turn on notifications for more updates from Proactive. #OndoInsurTech #LeakBot #InsurTech #CraigFoster #LibertyMutual #NationwideInsurance #SmartHome #WaterLeakDetection #TechStocks #Investing #USExpansion #StockMarket #InsuranceTech #FinancialGrowth

It's hoped a greater uptake in derelict sites grants will result in further increases in land value in Clare this year. A new report from the Irish Farmers Journal, shows prices rose by 16% from 2023, with land in the county worth on average €10,530 per acre and premium locations fetching as much as €15,000 per acre. The value of old houses on derelict sites has also increased in recent years, now adding as much as €100,000 in value to the land its situated on. Editor of Irish Country Living, Ciara Leahy has been telling me the less stringent planning regulations surrounding derelict sites has lead to it becoming a driving force behind land sales.

Its hoped the wider access to electric vehicle charging stations will encourage more people to make the switch away from petrol and diesel cars. It comes as new data released has identified that the Banner county ranks fourth in Ireland for the availability of public electric vehicle charging networks. The figures released by Geotab identify that Clare has one public charger for every seven battery powered cars in the county, with only Kerry, Mayo and Longford registering greater countywide availability. Chair of the Clare Electric Vehicle Owners Club, John Casey, claims greater research is now being produced, which dispels misconceptions around electric vehicle chargers.

Nafisa Akabor – Tech journalist and Founder. Recharged.co.za SAfm Market Update - Podcasts and live stream

Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Please visit answersincme.com/JUC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in obstetrics and gynecology and a cervical cancer survivor discuss strategies to increase human papillomavirus vaccination uptake, thereby reducing cervical cancer risk. Upon completion of this activity, participants should be better able to: Review guideline-recommended clinical strategies to reduce cervical cancer risk; Outline patient-focused strategies to increase acceptance of HPV vaccination across patient subpopulations; and Identify clinical approaches to enhance the uptake of recommended schedules for HPV vaccination.

References Nature 2024.volume 635, pages 1010–1018 Trad. 1923. "Midnight Special" CCR https://open.spotify.com/track/5jRQvcl66ovRTjUwzXziZA?si=b15d07dc2d1448db Hunter-Garcia 1979 "Althea" Grateful Dead https://open.spotify.com/track/7M7AwtGvWdMYudqx5Iuh1m?si=bd3d661d47d14992 Mozart, WA. 1779. Sinfonia Concertante K364. https://youtu.be/_0hTDZ0whpU?si=K3PDAEJUz08t6i-L Bruce, Jack 1968. "Train Time" Live. Wheels of Fire lp. Cream https://open.spotify.com/track/7cJgHvkMpSkZDw9aYWYTWm?si=eff3eaa37fb8440d --- Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Andy Cam and Todd Glister are looking into the lack of uptake in plumbing & heating apprenticeships and what the trade could to do get greater numbers in. Guests include: Kev Bates & Adam Hoyland

JCO PO author Dr. Michael J. Hall, Professor of Medicine, Chairman of the Department of Clinical Genetics, and Co-Leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center in Philadelphia, PA, shares insights into the JCO PO article, “Uptake of aspirin chemoprevention in patients with Lynch Syndrome.” Host Dr. Rafeh Naqash and Dr. Hall discuss the finding that only about 1 in 3 patients with Lynch Syndrome use aspirin for cancer chemoprevention. TRANSCRIPT  Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash podcast editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, I'm excited to be joined by Dr. Michael J. Hall, Professor of Medicine, Chairman of the Department of Clinical Genetics and co-leader of the Cancer Prevention and Control Program at the Fox Chase Cancer Center in Philadelphia, and also the lead author of the JCO Precision Oncology article entitled, “Uptake of Aspirin Chemo Prevention in Patients with Lynch Syndrome.” At the time of this recording, our guest disclosures will be linked in the transcript. Dr. Hall, welcome to the podcast and thank you for joining us today to explain and help the listeners understand your interesting research that was just published in JCO Precision Oncology. Dr. Michael J. Hall: Thank you so much for having me and really thanks for the interest in our work. I think it's an important subject and I hope people will also find it as interesting as we do. Dr. Rafeh Naqash: Absolutely. I think your research touches upon a few things. One, obviously, touches upon Lynch syndrome germline assessments of individuals. It also touches upon chemo prevention, prevention in general, and it also touches upon the knowledge and understanding of chemo prevention aspects. So to start off, I would like to ask you, for the sake of our listeners, many of whom who may not necessarily fully understand the length and breadth of Lynch syndrome, maybe perhaps some residents or trainees out there, could you tell us what Lynch syndrome is, what some of the mutations are, what the implications are, and then we can try to go and delve more into the research topic. Dr. Michael J. Hall: Sure, I'd be happy to. Lynch syndrome is probably, in the hereditary cancer genetics world, one of the most common hereditary risk syndromes we encounter. Recent estimates are that probably roughly about 1 in every 280 individuals in the population is a carrier of a pathogenic variant, one of the Lynch syndrome genes, there are roughly four. There's sort of a fifth gene that is also involved with Lynch syndrome, but really, we largely think about four genes in Lynch syndrome, MLH1, MSH2, MSH6, and PMS2. Over time we've begun to learn, and I'll say that the guidelines that we develop have become more specialized for each of those genes. They are not sort of all the same in the cancers they cause and the way they behave. But roughly, what is Lynch syndrome? It's a syndrome of DNA mismatch repair. So, individuals who have Lynch syndrome have some degree of deficiency in their ability to repair DNA via the mismatch repair system. Depending on the pathogenic variant that is within a family, that may be related to a more severe deficiency of mismatch repair, repair, editing, or for instance, with the PMS2 gene, we've learned over time that actually the degree of DNA repair deficiency is actually a milder phenotype. These individuals over a lifetime are at risk of a variety of different kinds of cancers, the most common being colon cancer. And the risk of that is variable by gene. With MLH1 and MSH2, it's close to 50% over a lifetime. With MSH6 and PMS2, somewhat lower. There are also risks of endometrial cancer, gastric cancer, ovarian cancer, pancreas cancer, a number of other ones. But they're all related again to the same underlying molecular deficiency, and that's this deficiency of being able to repair mistakes made in the DNA accurately. And so, mutations accumulate in the genome of cells in various tissues of the body. Dr. Rafeh Naqash: Thank you for that very simplified version of a very complicated topic otherwise. So, as you mentioned, these different genes have different implications. Perhaps some have higher risks for colorectal cancer than others. What are some of the current standardized approaches for screening or following these individuals over the course of their journey until perhaps either get detected with cancer or while they're being monitored? Dr. Michael J. Hall: Sure. It's a great question, because this is very much a moving target in this disease. I'm going to give you a quick second of history that up until maybe about six or seven years ago, we had uniform guidelines, really, that any Lynch syndrome pathogenic variant carrier should start colorectal cancer screening. Usually, we were recommending between the age of 20 and 25, and this was usually annual colonoscopy. And for years that was the standard. In more recent years, we've stuck to that tight interval, particularly in the higher risk genes, MLH1 and MSH2, although the guideline now reads every one to two years, because we recognize people need some degree of flexibility to live their lives. And there are people in the population who are more risk averse, and there are those who want a colonoscopy every year because they want to stick to that schedule. For MSH6, we recommend a somewhat later start at age 30, and that can be every one to three years for colon screening and for PMS2, similar recommendations, although I think there is a chance in the coming years, we may actually expand the screening interval even more, again, because the risks are somewhat lower. We still have ways to go in terms of screening for the other cancers in Lynch syndrome. I'll say that, for instance, endometrial cancer, which is the second most common cancer in this disease, we still struggle with what is the best way to screen women for a risk of endometrial cancer. Our guidelines in the past were always somewhat draconian, that once women sort of finish childbearing, they should immediately have a total abdominal hysterectomy and oophorectomy. And I'll say that with greater input from the gynecologic and GYN ONC community, we have somewhat softened those recommendations, especially for the endometrial cancer and also the age at oophorectomy, because we recognize that there were compensatory risks of taking the ovaries out too early in some women, risks of bone loss and cardiovascular disease. So those are the most common. For other tumors in Lynch syndrome, for instance, gastric cancer and pancreas cancer, the guidelines are still really evolving, and different groups have put out guidance for clinicians. And I'll say NCCN, which I participate in and help write those guidelines, has very good recommendations for docs. But I'll say that it is again, back to the idea that it's a moving target. And as we learn more, hopefully, we'll have better recommendations. Dr. Rafeh Naqash: I completely agree as far as a moving target is concerned, and we often look at the disconnect between the recommendations and then what's implemented or followed in the real-world setting. So I have a question in that context, and my question is, when you identify these individuals with Lynch syndrome, perhaps let's talk about academic settings, and then we can try to delve into how this might work in the real world community oncology settings, where the real world population actually exists, 60, 70% of individuals get treated in the community. So, when you talk about an academic center, what is the flow of the individual? Does the individual stay within the geneticist when they're diagnosed? Does the individual go to the primary care and the geneticist makes the recommendation and the primary care follows the recommendation? How does it work for you and what are some of the models that you've seen work best perhaps at different academic centers? Dr. Michael J. Hall: I think you get at a really great question. And I'll say there is really no one model. And I think models have to be fluid these days because people with Lynch syndrome are really being identified in more and more diverse settings, and by diverse means. I'll say at my own center, we are more of a traditional practice. So, we do the pre-test and the post-test counseling. Once we have counseled individuals identified Lynch syndrome, we will usually make referrals. If folks don't have a gastroenterologist that they have interacted with before, we keep them in our own group and follow them. But their Lynch syndrome home really sits both in a continuity clinic that I run for patients to come back and circle around every one to two years just to review guidelines and review their screening results. However, I do really make an effort to, first of all, keep primary care docs involved, because I think some of the things we recommend, it is critical that the primary care doc is aware so that patients are keeping up with some of the recommendations. For instance, we often recommend skin screening to make sure that folks have had at least one good skin exam somewhere in the 40s. And I think the primary care doc can be very helpful in making sure that happens. It is somewhat different, I think, in the community where many more patients with Lynch syndrome are being identified these days. I suspect that much more of the burden of making sure Lynch syndrome patients are well hooked in with a gastroenterologist and with a dermatologist and maybe a urologist probably does fall on that primary care doctor. In my experience, some primary care physicians have really kind of jumped up in and taken hold of this and really know their Lynch syndrome well, and I think that's amazing. I do, however, as kind of an expert in this area, I do get a lot of referrals in from the community as well, from docs who just feel that they may not have quite that expertise that they can get at a comprehensive center. So, someone may come in to me just for a consult to review what my recommendations would be, hear about research, hear about what's going on in the field, and those folks will often touch base with me again every couple year or so. Often, another thing I've started to experience is that I may meet people once or twice early on in their diagnosis, and then they go back to their primary docs and I may not hear from them again until something more profound happens in the family or into the patient and they get their screening colonoscopy and a stage 1 cancer is found. Often then, that's the patient who, after four or five years, will contact me again and say, “We haven't talked in a while, but something has happened, and can we re-consult about what would be the best way to do things?” Dr. Rafeh Naqash: Again, like you said, lots of moving targets, moving aspects to this whole care of these individuals. Do you think, in your experience, nurse navigation, maybe some centers have already implemented that perhaps you might have that, do you think nurse navigation could play a certain level of role? You know how in the multidiscipline care we have nurse navigators that coordinate care between radiation oncologists, medical oncologists, thoracic surgeons. So that's something that is being implemented. My second part of that question is telehealth in this case, maybe it's a little more difficult for somebody to drive three hours to come to you for a visit just to check in versus maybe virtually talking to you or your team getting a sense of where things are at in terms of their screening and their follow ups. Dr. Michael J. Hall: I think both are great, great questions and absolutely, we use both of those pieces in our model. And I know from colleagues that they do as well. So, in terms of navigation, we do have an embedded nurse navigator within our department. She joins and kind of helps facilitate all of our high risk follow up clinics. Mine, for GI, we have a high-risk prostate clinic, we have several high-risk breast clinics and those are populated by providers. We have a couple of nurse practitioners in my genetics group and a PA they are sort of the main provider in those clinics, but they are very much supported by that nurse navigator who, as you well point out, really helps with the coordination of the care. Telehealth as well, I do 100% support because you're absolutely right, if you look at a map of the United States and you first of all look at where there are good counseling services available, of course, there's ample counseling in the major metropolitan areas all over the U.S., but the minute you get outside of those counseling and then other management expertise, then– So we do have a model where particularly for folks who are from central Pennsylvania and sometimes more towards western Pennsylvania, I do have some individuals who've been identified with Lynch syndrome who telehealth in, again, for that follow up. A sort of side notes on telehealth, I think we learned a lot from the pandemic about how to use telehealth more effectively. And thank goodness, we've all gotten up to speed in medicine of how to be better telehealth providers. Unfortunately, I feel like with the pandemic kind of waning, there's been a little bit of a regression of the telehealth laws. So now if I want to do telehealth with someone who is from New Jersey, even though New Jersey sits very close to where I practice, it's more complicated now. Again, I have to get a license and same thing with New York and same thing with Delaware. I sort of wish we had a little bit of a better and welcoming system in the states where you could have easier ability to practice, especially when states were quite close using telehealth. But nonetheless, that's for another podcast, I think. Dr. Rafeh Naqash: Well, thank you again for some of those interesting aspects to this whole topic. But let's dive into the thing that we are here to talk about, which is aspirin in these individuals. So can you give us some context of why aspirin, what's the biology there and what's the data there, and then talk about why you did what you did. Dr. Michael J. Hall: So, we've known for many years that aspirin has preventive properties in terms of preventing colorectal cancer. Many observational studies and some interventional studies have shown us that aspirin has benefits for reducing the risk of colon cancer in an average risk population. There was even an interventional trial a number of years ago that looked at individuals who made polyps, and this looked at particularly adenomas, which we know are the precancerous polyps and adenoma prevention using aspirin. And that study clearly showed that aspirin had benefits for lowering risk of recurrent polyps and adenomas. Particularly even a lower dose of aspirin, 81 milligrams, was effective in that setting. Aspirin's also been studied in other hereditary risk syndromes, the most visible one being FAP, where data have shown that aspirin does help reduce polyp count in FAP, although is certainly not a perfect chemo prevention for that disease. So, in that background of knowing that aspirin has many benefits for colorectal cancer prevention, a study was initiated in the UK a number of years ago called the CAPP2 study, with its lead investigator being John Burn. And in this study, it was a two-arm factorial study that was not just aspirin, but they were also looking at resistant starch, which there was a lot of excitement about resistant starch back then. But in this study, they looked at using aspirin as a way of lowering risk of colorectal cancer in patients with Lynch syndrome. And that study, which was initially reported in The New England Journal, the initial outcomes did not actually show benefits in its first analyses of adenoma risk and colon cancer risk. But what they found over time was that there was a delayed effect and, in a follow, up paper looking at 10 plus years of follow up, they showed a substantial reduction in risk of colon cancer, about 40% risk reduction, which was really striking and exciting in the field to see such a large benefit from aspirin. Now, one caveat was in the analyses they performed, it was those individuals who were able to stick to the aspirin dose in that study, which was 600 milligrams a day. I always say to folks that back in the day, that was not a lot of aspirin, although I think these days we're much more skeptical about taking larger doses of any drug. So, 600 milligrams is roughly about two adult aspirin in the U.S. So those folks who were able to stick to that dose for at least two years were the ones who gained benefit from being on aspirin. And what was interesting is that benefit endured for really 10 years after those two years of being able to take aspirin. So, this was striking and it really changed our thinking about whether there may be chemo prevention options for folks with Lynch syndrome. However, and I think what formed the background of our study here was that there was a somewhat equivocal endorsement of aspirin by the major guidelines committees, mainly because, as we all know in oncology, we love one first big study, but we always really love secondary studies that solidify the finding of the first study. And so, because this was such a niche group and no one else out there was doing big aspirin studies when this result came out in 2011, we've sort of been waiting for many years for some follow up data. And the NCCN guidelines have always been a little bit equivocal that people could consider using aspirin to lower risk in their patients with Lynch syndrome, but without that kind of strong, “Everyone should do this.” And so, this has kind of formed the background of why we performed the study that we did. Dr. Rafeh Naqash: Interesting. And then you had a bunch of observations. One of the most important ones being that use of aspirin was pretty low. Could you dive into that and help us understand what were some of the factors surrounding those low implementation aspects? Dr. Michael J. Hall: Of course. So, what we were interested in then again in that background was, here's a high-risk population, docs are getting somewhat maybe ambiguous information from the guidelines, but what actually is going on out there in practice? How many patients are actually using aspirin? What doses are they using, and what are some of the factors that drive it? So, we performed a survey that actually occurred in two parts. One started at Fox Chase in our population here, and then we expanded it online to a convenience sample. Overall, we had 296 respondents. And yeah, what we found actually was the uptake of aspirin was only about roughly 30%, 35% or so among patients who were eligible to take aspirin. When you actually drill down to those people actually taking aspirin because they wanted to prevent Lynch syndrome, it was even lower. It was in the range of 25% to 30%. This somewhat surprised us. And then when we looked at the doses that people were using, of course, thinking back to that 600-milligram dose that was tested in the study, we found actually that more than half of folks were taking low dose aspirin, like an 81 milligram, and only about 8% of our study participants were using that 600-milligram range. So, again, I would say this somewhat surprised us because we thought it might be higher than this. I'll say as a somewhat caveat to this though, is that back to my comment about we always like another study that confirms our findings, and at a meeting earlier this year, there was a study performed in a New Zealand population by a medical oncologist named Rebecca Tuckey. And she actually found almost the same identical results that we did in the New Zealand population - very, very similar uptake rates of aspirin in the New Zealand population with Lynch syndrome, so kind of confirming that something we've stumbled upon appears to be true. But how do we understand why some folks use aspirin and why others don't in this condition? Dr. Rafeh Naqash: You had a very robust question there from what I saw in the paper. And some of the questions that I had around that was, did you or were you able to account for demographics, education level of the individuals? Were you also able to assess whether these individuals felt that they had been counseled appropriately when they met with either a primary care physician or of any provider on the genetic side, physician or non-physician? So how did you get an assessment of whether it was an apples-to-apples comparison or were there a lot of confounders. Dr. Michael J. Hall: Very good question. And of course, in the setting, unfortunately, we weren't interviewing people, which we could have gotten much richer data in some ways. And there were other things we were looking at in this survey as well, so our aspirin questions, we had a number of them, but perhaps in retrospect, it would have been nice to even have more. We did have some common covariates, age, sex, ancestry, marital status, which gene was affected, whether they had a history of cancer. We did not have education, unfortunately. And I think your question is a great one, but we did not actually ask folks about whether they had been counseled by their provider or their genetic counselor or someone else about whether they should use aspirin or not. We simply wanted to see whether folks were using it. We did ask them again whether they were using it because they wanted to lower their risk of a Lynch syndrome cancer or whether they were using it for another reason or a combination of both. So, yes, in retrospect, we actually do have another study plan to kind of drill deeper into these questions of is it more of a hesitancy question? Is it more of a question of just not as much awareness? Are there other reasons? I think there's a lot to answer, and I think answering these questions is really important because we both want to make sure we're talking about interventions that we think can help people, but we need to understand also some of the barriers they may face. And if people do have barriers to some forms of chemo prevention or I think about some of the vaccine research that's going on right now, if the kinds of things that we're working on to develop are actually not going to be palatable to the patient, the population, then I think we kind of need to step back and say we need to maybe understand what people want so that we can have a good meeting of what's going to work and what's going to fit the needs and lifestyles of our patients. Because these are things they might have to do for many, many years and starting maybe even in their 20s or 30s. So, it makes a difference. Dr. Rafeh Naqash: From what you learned in the study, are you thinking of any subsequent interventional approaches, whether they involve a simple phone call to the patient regularly or perhaps, even though I'm not a big fan of EMR prompts, like an EMR prompt of some sort, where they talk, where they're instructing the provider, whoever is seeing the patient physician or the APP or the geneticist that, “Hey. Did you counsel the patient?” And its sort of a metric how in the oncology side they say, “Well, your metric is you should stage all patients and you should talk about toxicities from a reimbursement standpoint and also from a quality improvement metric standpoint. “Is that something you're thinking of? Dr. Michael J. Hall: 100%. So, when we looked at the barriers, many of the kind of the things that were the strongest predictors of who used aspirin versus who didn't were really patients' perceptions of whether aspirin would cause side effects or whether aspirin would be burdensome to take on a daily basis, also, just how much benefit they thought would come from taking aspirin. So, I think there's, number one, I think an intervention and our next delve into this as an interventional study would be both education about the delta prevention benefit that you get from aspirin, the safety profile of aspirin, which is really quite excellent. And also, I think the data that are so important that in this study by Burn et al, it was actually only two years of intervention that then paid off for 10 years down the line, right? So, I think that's important. The other thing that we actually learned as an aside in this study was actually the kind of intervention that patients wanted the most was actually not a drug and was not a vaccine and was not another kind of special scope to stick somewhere. What they actually were most interested in were interventions related to diet. People really see diet as being an important part of health, or I should say diet and nutrition. And so, I think a subsequent study would perhaps wed both a nutritional intervention of some kind with a chemo prevention in some sort of time limited fashion, so that folks felt like they were both focusing on something that was more important to them, but also, something that was related to the study that we wanted to look at. So that's kind of my idea of where we're going to go in the future with this. Dr. Rafeh Naqash: Excellent. Sounds like the next big RO1 for your group. Dr. Michael J. Hall: Let's hope so. Dr. Rafeh Naqash: Well, I hope the listeners enjoyed talking about the science and learning about aspirin Lynch syndrome. The last couple of minutes are about you as an individual, as an investigator. Can you tell us what your career journey has been like, how you ended up doing what you're doing, and perhaps some advice for early career junior investigators on what this whole space looks like and how you pace yourself and how they can learn from you? Dr. Michael J. Hall: I really got interested in oncology during my residency training. I really found that I really liked oncologists. I found them to be a bit more of a science focused group. They liked research, but you're in oncology because you understand the fears and the challenges of cancer. And so, it's both a combination of that love of science, but also that real human touch of taking care of people. The thing I always tell my fellows as well is the other thing I love about oncology is if you tell people they don't have cancer, they don't want to come back to you. Now, of course, that's modified in the prevention setting. But I really like that when people come to me in my GI oncology clinic, it's because they have a diagnosis and if I say you actually don't have cancer, they go off to their life, and so you're really spending your time on real subjects. The person who really got me most interested in Lynch syndrome and this kind of prevention research was a mentor from University of Chicago, Funmi Olopade, who really has been an enormous mentor for many, many people in the field. Actually, three people in my fellowship class all went on to careers related to genetics and genomics. So, she's been highly influential and continues to mentor me even in my mid-career. I think in terms of pearls or what keeps this interesting for me, I think as much as oncology treatment and new drugs and trials is super exciting, I love being able to step away from that into my genetics and prevention population and kind of focus on treating people in a different format. Patients who are healthy but are worried about cancer because of a family history or carrying a gene or otherwise, and I feel that that's where I can have also an important impact, but on a different level in educating people and helping them understand how genetics works in an understandable and simple way, but also giving them some tools. And one reason for this study, and the reason I study preferences related to prevention is, again, I don't want to just develop something and spend 10, 15 years of my life developing some intervention that everyone looks at and is like, “I don't really want to do that.” I want to really understand what it is that is important to the patients so that we can hopefully work together to develop things that can not only have impact but have impact on a wide scale. Dr. Rafeh Naqash: Awesome. You mentioned Dr. Olopade. I crossed paths with her actually at an international medical graduate community of practice session earlier this year at ASCO where she talked about her journey as an immigrant, talked about how she started, the kind of impact that she's had. It was obvious evident in the picture that she showed with all her mentees who have kind of gone all over the world. So that was very phenomenal. And it's surprising how small of a world we live in. Everybody knows everybody else. Dr. Michael J. Hall: It's crazy. More so than anyone I think I've met in my career; she is really a huge believer in mentorship and spending that extra time with your mentees. And she has been someone who has continued to promote me as an investigator and build me up and get me involved in things. And like I said, I've been in oncology now for quite a few years. But having that person who I think is always thinking about their trainees and people who have learned and grown under them, because what it does is it gives you that fire as well as an investigator to do the same thing for the people that you are a mentor for and train. So, I try to be just as good of a mentor to my genetic counselors and the fellows who come through me and my APPs to give them opportunities to get them excited about research and when they have these big moments to do that. So, yeah, I know Funmi just has had a huge impact on the field of genetics. I still remember some of our early conversations on the wards when she said to me, “Oh, this is such an interesting case. We don't really have anyone who's studying Lynch syndrome so much right now and you should really get into this area.” And I remember thinking, “Okay, I want to develop a niche and here's a niche that's waiting.” Dr. Rafeh Naqash: Clearly it paid off big time and you're paying it forward with your mentees. So, thank you again for joining us. This was an absolute pleasure. Hopefully, the listeners learned a lot about the science and also your journey and how you're trying to impact the field. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinion, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.      

It's cold and flu season and many New Brunswickers are looking to get their shots, including the updated COVID vaccine. We'll check in with the pharmacists association to get an understanding of the roll out so far.

Listen in as Rebekah Fenton, MD, MPH, and Sharon G. Humiston, MD, MPH, discuss strategies to achieve health equity in HPV vaccination, including:Trends among males vs femalesMessaging considerations for those from diverse populations (eg, LGTBQ+ and rural communities)How healthcare professionals can address barriers to careThen, hear answers from the experts to frequently asked questions regarding HPV vaccination recommendations, timing, and example case studies. Presenters:Rebekah Fenton, MD, MPHAdolescent Medicine PhysicianAlivio Medical CenterChicago, IllinoisSharon G. Humiston, MD, MPHDirector for ResearchAssociate Editor of IZ-ExpressImmunize.orgRochester, New YorkTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Follow along with the slides: https://bit.ly/4flDxYbLink to full program: https://bit.ly/4f06tW4

Listen in as Sharon G. Humiston, MD, MPH, discusses current trends in HPV, including:Incidence and prevalence trends in the USSex-related features of HPV-attributable cancersHow HPV vaccination uptake can prevent certain types of cancerCurrent guidelines and recommendations for HPV vaccinationPresenter:Sharon G. Humiston, MD, MPHDirector for ResearchAssociate Editor of IZ-ExpressImmunize.orgRochester, New YorkTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Follow along with the slides: https://bit.ly/4flDxYbLink to full program: https://bit.ly/4f06tW4

Listen in as Rebekah Fenton, MD, MPH, and Sharon G. Humiston, MD, MPH, discuss strategies to improve your messaging techniques with the HPV vaccine, including:Persisting in vaccine recommendation after initial refusalEducating patients and their families togetherEnsuring staff are trained to correctly answer questionsKnowing when interested patients in your state can consent to vaccination without needing parental consentPresenters:Rebekah Fenton, MD, MPHAdolescent Medicine PhysicianAlivio Medical CenterChicago, IllinoisSharon G. Humiston, MD, MPHDirector for ResearchAssociate Editor of IZ-ExpressImmunize.orgRochester, New YorkTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Follow along with the slides: https://bit.ly/4flDxYbLink to full program: https://bit.ly/4f06tW4 

This Real Science Exchange podcast episode was recorded during a webinar from Balchem's Real Science Lecture Series. The primary goal of a replacement program is to raise the highest quality heifer that can maximize profits when she enters the lactating herd. She carries no limitations that would detract from her ability to produce milk under the farm's management system. Ideally, one would wish to optimize profits by obtaining the highest quality heifer at the lowest possible cost, usually in the least amount of time. Dr. Van Amburgh presents a snapshot evaluation of benchmarks to assess the potential quality of replacements. (3:47)When does the process of creating a quality heifer start? Probably before conception. In non-pasture herds, the first lactation cows giving birth to heifers produced about 1000 pounds more milk in the first two lactations. Heifers whose dams were supplemented with choline during the pre-fresh period had higher birth-to-yearling average daily gains and improved immunity. Choline also appears to enhance the quality of colostrum via increased absorption of IgG. This implies that maternal programming extends beyond the uterine environment via ingestion of milk-borne factors, known as the lactocrine hypothesis (14:29)After the calf is born, the goal is anabolism or growth. The dam communicates with the calf via colostrum to direct calf development after birth. Not only does colostrum provide immunoglobulins, but it also contains a large amount of nutrients and non-nutrient factors that support gut maturation. In particular, IGF-1 and insulin may act on receptors in the gut to stimulate cell proliferation, cell differentiation, and protein synthesis. Dr. Van Amburgh summarizes several studies that showed increased colostrum feeding improved pre- and post-weaning growth and development. While the immunoglobulin content of colostrum is essential for passive immunity, the other components in colostrum are responsible for the increased growth performance. (27:39)The hormones and growth factors in colostrum enhance protein synthesis, enzyme expression, and gastrointestinal tract development. This implies that the gut is now an even stronger barrier to infection, with more surface area for digestion and absorption, with an increased capacity to digest nutrients due to higher enzyme excretion. (36:33)To investigate the impact of non-nutrient factors in colostrum, studies were designed where calves were fed either colostrum or milk replacer with the same nutrient content. Glucose uptake was increased for colostrum calves even though both groups received similar nutrient content. Plasma glucagon was higher in colostrum calves, indicating better glucose status and higher reserve capacity. Plasma protein levels were higher in colostrum calves, suggesting more amino acids available for growth and protein synthesis. Plasma urea nitrogen was lower for colostrum calves, indicating fewer amino acids were used for gluconeogenesis leading to more efficient growth. (46:55)What happens to immune cells in colostrum? Leukocytes and other immune-related cells in colostrum are trafficked into the circulation of the calf. Maternal leukocytes can be detected in the calf by 12 hours, peak at 24 hours, and disappear by 48 hours. Long term, there appears to be greater cellular immunity in calves that received whole colostrum compared to cell-free colostrum. Uptake of cells from colostrum enhances cellular immunity in calves by providing, mature, programmed cells from the dam. (52:24)The take-home message for colostrum management is to feed colostrum for four days. Give first-milking colostrum within six hours of birth and again at 12 hours. Give second-milking colostrum for day two feeding and third- and fourth-milking colostrum for days three and four. (56:04)Dr. Van Amburgh answers a few questions from the webinar audience about dry cow management for colostrum quality and quantity, the impacts of pasteurization of colostrum on components, and the efficacy of colostrum replacers. Watch the full webinar at balchem.com/realscience. (58:25)Please subscribe and share with your industry friends to invite more people to join us at the Real Science Exchange virtual pub table.  If you want one of our Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll mail you a shirt.

On this episode of the Strip-Till Farmer podcast, brought to you by Yetter, University of Illinois soil scientist Andrew Margenot shares key takeaways from his long-term phosphorous (P) studies. Margenot's research group focuses on everything from NPK recommended rates, soil test values, removal rates and more. He's currently leading the charge on a project to analyze thousands of soil samples dating back to the late 1800s — the largest soil samples archive in the world.

Pistachios alternate bear, which changes the dynamics of nitrogen uptake and allocation within the tree on a year to year basis. To add to this, the newer cultivars, Golden Hills and Lost Hills, alternate bear less than Kerman, especially when they are planted on the high vigor UCBI. Doug Amaral (UCCE Kings County) decided it was time for an update on the nitrogen demand curves, and we discuss what he's found in this episode.Come to an upcoming extension meeting!Sacramento Valley San Joaquin Valley (scroll to the bottom) The views, thoughts, and opinions expressed are the speaker's own and do not represent the views, thoughts, and opinions of the University of California. The material and information presented here is for general information purposes only. The "University of California" name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service.Follow us on Twitter! @SacOrchards and @SJVtandvThank you to the Almond, Pistachio, Prune, and Walnut Boards of California for their kind donations. Thank you to Muriel Gordon for the music.

Explore the importance of understanding and addressing vaccine hesitancy and consider the impact on uptake of vaccination strategies. Our discussion will consider the impact of the pandemic and the challenges and solutions associated with vaccine hesitancy in both HCPs and the public to build trust and vaccine uptake in the post-pandemic era. The publication of this podcast series was funded by Novavax.

Are you up to date on your vaccines? How about your children? Amesh Adalja, a critical care medicine physician and pandemic preparedness expert at Johns Hopkins, says a look at the data on vaccine uptake is cause for alarm.  Amesh … Vaccine uptake is lackluster, and that's a problem, Elizabeth Tracey reports Read More »

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond.  Fierce Pharma's Zoey Becker chats with Gregg Sylvester, M.D., Chief Health Officer at CSL Seqirus, to get insight on what we might expect to see from this upcoming flu season. He also explains efforts to increase vaccine uptake through awareness and education campaigns.   To learn more about the topics in this episode:  Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season CDC starts 'Wild to Mild' campaign to reverse falling flu vaccine use in key groups American Lung Association, Sanofi urge high-risk communities to grab their flu shots in 'United Against Flu' campaign See omnystudio.com/listener for privacy information.

Health Affairs' Editor-in-Chief Alan Weil interviews Dongzhe Hong of Brigham and Women's Hospital and Harvard University on his recent paper that explores how patient and prescriber factors play into biosimilar uptake in the US.Order the August 2024 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.

In his weekly clinical update, Dr. Griffin discusses global transmission of mpox, the different clades of the virus and associated pathogenesis, vaccination vs antiviral therapy against mpox and the US's aid response for controlling the African outbreak before reviewing the recent statistics on SARS-CoV-2 infection, authorization and approval of updated COVID vaccines, the economic benefit of an annual COVID vaccine and if the first updated vaccines against XBB.1.5 were effective, where to find PEMGARDA, breakthrough infections when administering PEMGARDA, when to use convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, and how long COVID differs in children and adolescents. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode mpox epidemic caused by monkeypox clade I in affected African countries (European Centre for Disease Prevention and Control) mpox in Pakistan (Reuters) mpox imported into Pakistan (UNMC Global Center for Health Security) mpox domesticated in Taiwan (Focus Taiwan: CAN English News) clade IIb not Ib in Taiwan (bne Intellinews) WHO: mpox public health emergency of global care (NY Times) Vaccines didn't turn back mpox…..people did (NY Times) Deadlier mpox version in Thailand (NY Times) Antiviral tecovirimat….not so much (NIH News) What about vaccines? (Bavarian Nordic) Invest or not to invest Barvaian Nordic pox vaccine manufacturer? (Yahoo! Finance) US to support Africa's mpox response (CIDRAP) $35M to support mpox outbreak response in central and eastern Africa (USAID From the AMERICAN PEOPLE) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) FDA approves and authorizes updated mRNA COVID-19 vaccines (FDA) Novavax still working on updated COVID-19 vaccine (novavax) COVID-19 variant update (CDC & IDSA) Economic benefit of annual COVID-19 vaccination (JID) Early COVID-19 XBB.1.5 vaccine effectiveness (Influenza and other respiratory viruses) Uptake of COVID-19 vaccines and associated hospitalization due to COVID-19 in pregnancy (Vaccine) Novavax heterologous booster demonstrates lower reactogenicity (JID) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Breakthrough from pemivibart/permgarda (bioRxiv) CDC Quarantine guidelines (CDC) Early phase of SARs-CoV-2 infection (COVID.gov) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (ID Society) Drug interaction checker (University of Liverpool) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Long COVID differs in children and adolescents (JAMA Network) Letters read on TWiV 1142 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In this episode, we meet Dr. Shawn Hayden, Medical Director for Friends for All and local physician We discuss PrEP prevention and the science around it.

Interview with Charles Stoecker, PhD, and Yin Wang, MA, authors of State COVID-19 Vaccine Mandates and Uptake Among Health Care Workers in the US. Hosted by JAMA Network Open Associate Editor Angel N. Desai, MD, MPH. Related Content: State COVID-19 Vaccine Mandates and Uptake Among Health Care Workers in the US

Resources provided by podcast participants:National Lung Cancer Round Table-https://nlcrt.org/Lung Plan- https://nlcrt.org/lungplan-overview/Standing Facility Lung Program-https://cancer.wvumedicine.org/about-us/programs/lung-cancer-screening-programMobile Lung Program- https://cancer.wvumedicine.org/about-us/programs/mobile-cancer-screening-program/lucasLiving Beyond Cancer Podcast Series(Patient, Survivors, and Caregivers)-https://cancer.wvumedicine.org/about-us/podcasts/

Host Gil Bashe and Gregg Masters welcome their guest, who's making his third appearance on the show, tech influencer, global thought leader, keynote speaker and author John Nosta, president at NOSTA LABS. They discuss the rollout of AI and it's practical uptake into the health and live sciences ecosystems. John weighs in on the range of LLMs (large language models) and the more promising opportunities presented in our healthcare delivery, and life sciences markets. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Dr. Centor discusses the uptake of newer antibiotics for difficult-to-treat resistant infections with Dr. Sameer Kadri.

In this episode, Roger Bedimo, MD, MS, FACP, discusses strategies to overcome health disparities to improve PrEP uptake, including:Targeting key populations that would benefit from PrEP but have low rates of uptake, such as transgender women and people who inject drugsAddressing intersectionalityOvercoming implicit biasAddressing PrEP inequity by geographic regionExpanding PrEP uptake by expanding HCPs who prescribe itImproving PrEP education for both patients and HCPsPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program: https://bit.ly/49x0W6DFollow along with the slides: https://bit.ly/3KmW4pNGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Using common case scenarios, Robert H. Hopkins, Jr., MD, MACP, and Laura P. Hurley, MD, MPH, discuss strategies for optimizing shingles vaccine uptake, including:The pathophysiology of shingles to better understand risk and burdenCDC guidelines and ACIP shingles vaccine recommendations, including considerations for those who are immunocompromised Strategies for optimizing shingles vaccine uptake no matter the clinical settingHow to address shingles vaccine‒related adverse events Addressing insurance-related concerns Presenters:Robert H. Hopkins, Jr., MD, MACPProfessor of Internal Medicine and PediatricsChief, Division of General Internal MedicineUniversity of Arkansas for Medical SciencesSchool of MedicineLittle Rock, ArkansasLaura P. Hurley, MD, MPHGeneral Internist and Health Services ResearcherAssociate Professor of MedicineDepartment of General Internal MedicineUniversity of Colorado Anschutz Medical CampusAurora, ColoradoLink to downloadable slides:https://bit.ly/4aWn6jhLink to full program:https://bit.ly/4aWBiJ0Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

A round-up of the main headlines in Sweden on April 18th 2024. You can hear more reports on our homepage www.radiosweden.se, or in the app Sveriges Radio Play. Presenter: Dave RussellProducer: Michael Walsh

In this episode of the IoT For All Podcast, Curtis Govan, President of Americas for floLIVE, joins Ryan Chacon to discuss hyperlocal global IoT connectivity. The conversation covers the critical factors companies need to consider when adopting IoT solutions, compatibility and data regulation requirements across different countries, single SIM technology, the benefits of controlling core infrastructure, and upcoming technological advancements, including NB-IoT over satellite. Curtis Govan is President of Americas for floLIVE. He is an accomplished leader with 25+ years of experience and expertise in technology, business development, and sales. Previously, he was GM and Global VP Dealer and Heavy Equipment at Uptake, an industry leader in industrial artificial intelligence and IoT. He also spent 12 years with Cisco Jasper where he held several roles with the most recent being Head of Global Sales Business Development and Regional Managing Director - Canada. floLIVE has designed and developed an elastic, robust core cellular infrastructure that is the largest in the world. Through this powerful infrastructure, the company offers numerous services to mobile operators, IoT MVNOs, and global enterprises seeking seamless, compliant, high performance connectivity anywhere in the world. With a global carrier library that is based on interconnected local core mobile networks, floLIVE ensures low latency, high performance, and full compliance with privacy acts, data regulations, and roaming restrictions. More than 20 mobile operators are on board the platform, giving companies multi-tier connectivity access. Through direct access to their network, customers can monitor their devices, access real-time network events and usage, switch operators remotely, and troubleshoot failures ahead of time, providing a seamless experience that keeps devices connected at all times. Through one integration, one SKU, and one platform, customers have endless possibilities for connectivity. Discover more about connectivity and IoT at https://www.iotforall.com More about floLIVE: https://flolive.net Connect with Curtis: https://www.linkedin.com/in/curtis-govan-53b0144/ (00:00) Intro (00:08) Curtis Govan and floLIVE (01:42) The connectivity component of IoT (03:53) Exploring hyperlocal global connectivity (13:48) The benefits of owning core infrastructure (16:27) Connectivity considerations for IoT buyers (19:15) Looking ahead: NB-IoT over satellite (21:34) Learn more and follow up SUBSCRIBE TO THE CHANNEL: https://bit.ly/2NlcEwm​ Join Our Newsletter: https://www.iotforall.com/iot-newsletter Follow Us on Social: https://linktr.ee/iot4all Check out the IoT For All Media Network: https://www.iotforall.com/podcast-overview

In this episode Jesse Hackell, MD, FAAP, offers strategies for improving vaccine uptake in hesitant families. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Pearl Chang, MD, about how newborn nurseries react to marijuana use and breastfeeding. For resources go to aap.org/podcast.

Nik from Rooted Leaf Nutrients (use code GROWCAST) is back on the show to continue our nutrient deep dive series! This time we take a step away from soil fertilizer elements and instead discuss PH, EH, and nutrient uptake. Nik talks about what PH is (potential of hydrogen) and why the amount of hydrogen can be used to deduce how available nutrients will be in the solution. Nik talks about the donation of hydrogen atoms and how chelation works inside a solution- highlighting that these availability processes take place totally independently of each other. This leads to conversation about EH, and Nik talks about the redox cycle as well as how oxygenation plays a role in plant health. Nik ties it all together back to photosynthesis and nutrient availability as a whole, and emphasizes how PH is NOT the only determining factor in nutrient availability, just one among other factors that may even be more important in certain scenarios... GrowCast Membership Weekly Live Streams - Personal Garden Advice- 100s of HOURS of Bonus Content  - MEMBERS ONLY DISCOUNTS! Join the greatest community in cannabis! GrowCast Seed Co If you are reading down this far... Go to Seed Co page, you may find a new drop live right now! *Rooted Leaf Carbon Based Nutrients - liquid organic nutrients with NO NEED to PH! Visit www.rootedleaf.com and use code GROWCAST for 20% off, just add to filtered water and watch the EXPLOSIVE growth!*

Dr. James White is a professor of Plant Pathology at Rutgers University. Dr. White obtained an M.S. in Mycology and Plant Pathology from Auburn University and a Ph.D. in Mycology from the University of Texas at Austin in 1987. Dr. White specializes in symbiosis research, particularly endophytic microbes. He is the author of more than 180 articles and author and editor of reference books on the biology, taxonomy, and phylogeny of fungal endophytes, including Biotechnology of Acremonium Endophytes of Grasses (1994), Microbial Endophytes (2000), The Clavicipitalean Fungi (2004), The Fungal Community: Its Organization and Role in the Ecosystem (2005), and Defensive Mutualism in Microbial Symbiosis (2009). The overall hypothesis of this research is that bacterial and fungal endophytes of the plant microbiome function to defend plants from stress and provide nutrients that enhance the growth and development of plants. In this episode, James and John discuss: How plants get nutrients through the rhizophagy cycle Important microbes lost from commercial seed production  Indigenous wisdom in seed production Bacteria changing the behavior of fungal populations through nutrients How endophytes benefit plants  Reshaping agriculture to be based on how plants actually grow How plants cannot grow without microbes in their cells Additional Resources To take the course led by Dr. James White that teaches the Rhizophagy cycle, please visit: https://kindharvest.ag/courses/ra-ur-understanding-rhizophagy/ About John Kempf John Kempf is the founder of Advancing Eco Agriculture (AEA). A top expert in biological and regenerative farming, John founded AEA in 2006 to help fellow farmers by providing the education, tools, and strategies that will have a global effect on the food supply and those who grow it. Through intense study and the knowledge gleaned from many industry leaders, John is building a comprehensive systems-based approach to plant nutrition – a system solidly based on the sciences of plant physiology, mineral nutrition, and soil microbiology. Support For This Show & Helping You Grow Since 2006, AEA has been on a mission to help growers become more resilient, efficient, and profitable with regenerative agriculture.  AEA works directly with growers to apply its unique line of liquid mineral crop nutrition products and biological inoculants. Informed by cutting-edge plant and soil data-gathering techniques, AEA's science-based programs empower farm operations to meet the crop quality markers that matter the most.  AEA has created real and lasting change on millions of acres with its products and data-driven services by working hand-in-hand with growers to produce healthier soil, stronger crops, and higher profits. Beyond working on the ground with growers, AEA leads in regenerative agriculture media and education, producing and distributing the popular and highly-regarded Regenerative Agriculture Podcast, inspiring webinars, and other educational content that serve as go-to resources for growers worldwide. Learn more about AEA's regenerative programs and products: https://www.advancingecoag.com/ ~  VIDEO: To learn more from John Kempf about regenerative agriculture, watch this conversation between John and three AEA grower partners about how regenerative agriculture is changing lives and conventional farming: https://youtu.be/n9U6GwbYPDk

As we kick off a brand new year of podcasts, this week Robert speaks with Behyad Jafari, CEO of the Electric Vehicle Council in Australia.    As you may know our first Everything Electric live event of 2024 kicks off in Australia at the Sydney Olympic Park on February 9th, 10th & 11th, and in the lead up to this event we're showcasing all the electrifying things happening ‘Down Under'!   Working with all stakeholders across the sector, from OEMs to Banks, big Retail, Government and of course consumers, the EVC of Australia is a leading force in pushing change forward in a country that has huge opportunities for an electrified future.   This podcast is a fascinating insight into some of the challenges and triumphs Behyad and his team have faced in their mission to accelerate the uptake of EVs in Australia     Why not come and join us at our next event: https://fullycharged.live/     Support our StopBurningStuff campaign: https://www.patreon.com/STOPBurningStuff   Become a Fully Charged SHOW Patreon: https://www.patreon.com/fullychargedshow   Become a YouTube member: use JOIN button above   Buy the Fully Charged Guide to Electric Vehicles & Clean Energy : https://buff.ly/2GybGt0       Subscribe for episode alerts and the Fully Charged newsletter: https://fullycharged.show/zap-sign-up/   Visit: https://FullyCharged.Show Find us on Twitter: https://twitter.com/fullychargedshw Follow us on Instagram: https://instagram.com/fullychargedshow   #fullychargedpodcast #fullychargedshow #everythingelectric #fullychargedlive

In this episode, Dr. Osterholm and Chris Dall discuss the JN.1 variant, the rising levels of SARS-CoV-2 in wastewater, and the low uptake of the COVID-19, RSV, and influenza vaccines. Dr. Osterholm also shares his thoughts on hospital capacity issues in the U.S. and shares the latest "This Week in Public Health History" segment. Support this podcast